The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
November 27, 2018
–Three abstracts accepted, including oral presentation on multiple myeloma clinical data–
[/vc_column_text][vc_column_text]Houston, TX – November 27, 2018 – Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today reported that data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018). The studies describe results achieved using multi-tumor antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan Vera, and exclusively licensed to Marker.
Among the highlights, results from an ongoing Phase 1 study in patients with multiple myeloma will be reviewed in an oral presentation by Premal Lulla, M.B.B.S., Assistant Professor of Medicine at the Center for Cell and Gene Therapy, Hematology-Oncology, at the Baylor College of Medicine.
ASH 2018 will take place in San Diego, CA from December 1-4.
Oral Presentation Details:
Title: Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma (Abstract # 1014)
Date: Monday, December 3, 2018
Time: 7:30 p.m. PST (San Diego Convention Center, Ballroom 20D)
Poster Presentation Details:
Title: Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells (Abstract #1685)
Date: Saturday, December 1, 2018
Presentation Time: 6:15 p.m. – 8:15 p.m. PST (San Diego Convention Center, Hall GH)
Title: Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens (Abstract #2693)
Date: Sunday, December 2, 2018
Presentation Time: 6:00 p.m. – 8:00 p.m. PST (San Diego Convention Center, Hall GH)
The presentations will contain results beyond what are available in the abstracts on the ASH website.[/vc_column_text][vc_empty_space height=”4px”][vc_column_text][mrkrdisclaimertrout]